Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate

  title={Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate},
  author={Omar Sadeeq Din and Penella Woll},
  journal={Therapeutics and Clinical Risk Management},
  pages={149 - 162}
Gastrointestinal stromal tumor (GIST) is a rare primary neoplasm of the gastrointestinal tract, mesentery, or omentum. In the past, surgery has been the only effective treatment. The diagnosis and treatment of GIST has been revolutionized over the past decade, since expression of the receptor tyrosine kinase KIT was shown to occur on these tumors. Mutations in this proto-oncogene commonly cause constitutive activation of the KIT tyrosine kinase receptor, an important factor in the pathogenesis… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
12 Citations
103 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 12 extracted citations


Publications referenced by this paper.
Showing 1-10 of 103 references

Comparison of two doses of imatinib for the treatment of unre - sectable or metastatic gastrointestinal stromal tumors ( GIST ) : A meta - analyis based on 1 , 640 patients ( pts )

  • MM VanGlabbeke, K Owzar, C Rankin
  • J Clin Oncol , 2007 ASCO Annual Meeting…
  • 2007

Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group

  • A Le Cesne, I Ray-Coquard, M Bui
  • J Clin Oncol,
  • 2007
1 Excerpt

GIST clinical trials search [online

  • NCI.
  • Accessed 5 May 2007. URL:…
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…